Revumenib is a first-in-class small-molecule menin inhibitor indicated for the treatment of relapsed or refractory acute leukemias characterized by KMT2A rearrangements. By blocking the interaction between… Read more



![Chemical structure of N-[trans-4-[[[(4-Methylphenyl)sulfonyl]oxy]methyl]cyclohexyl]ethanesulfonamide](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2F2169920-33-4-N-trans-4-4-Methylphenylsulfonyloxymethylcyclohexylethanesulfonamide.png&w=3840&q=75)




Revumenib is a first-in-class small-molecule menin inhibitor indicated for the treatment of relapsed or refractory acute leukemias characterized by KMT2A rearrangements. By blocking the interaction between menin and KMT2A fusion proteins, this agent effectively disrupts specific transcriptional pathways essential for leukemogenesis. To support pharmaceutical development and manufacturing, this category provides high-quality reference standards, including the active pharmaceutical ingredient, critical synthetic intermediates, degradation products, and process-related impurities. Laboratory professionals utilize these compounds for impurity profiling, analytical method validation, and stability testing to ensure strict regulatory compliance. Additionally, the availability of stable isotope labelled compounds facilitates precise quantitative analysis and pharmacokinetic studies. These materials are fundamental to maintaining consistent quality control and safety assessments during the research and production of this complex therapeutic agent.